Effects of upadacitinib or adalimumab on pain in rheumatoid arthritis and psoriatic arthritis: results from randomised phase 3 studies
Upadacitinib effectively reduced pain in active RA and PsA, including in patients with AoI. The greater pain relief observed in RA with upadacitinib versus adalimumab might indicate both direct (relieving non-inflammatory pain) and indirect (suppressing inflammation) effects.
Authors
- P. Taylor
- A. Garrison
- Ralph Lippe
- Tianming Gao
- Arthur Kavanaugh
- Bruno Fautrel
- Philip J Mease
- Diane Caballero
- Charles Phillips
- Tsutomu Takeuchi
Institutions
- Providence College (US)
- University of Washington (US)
- Keio University (JP)
- Nuffield Orthopaedic Centre (GB)
- University of California System (US)
- AbbVie (United States) (US)
- Sorbonne Université (FR)
- University of Oxford (GB)
- Swedish Medical Center (US)
- Pitié-Salpêtrière Hospital (FR)
- Université Laval (CA)
- Saitama Medical University (JP)
Publication Details
- Journal
- RMD Open
- Published
- 2026-01-01
- DOI
- https://doi.org/10.1136/rmdopen-2025-005867
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- Eisai
- Swedish Orphan Biovitrum
- Nordic Pharma Group
- Medac
- Pfizer Japan
- Chugai Pharmaceutical
- Eli Lilly Japan